Pfizer's 7.5% Dividend: Income Haven or House of Cards?

Pfizer's attractive 7.5% dividend yield, supported by a 16-year dividend growth track record and current cash flow, is juxtaposed against significant revenue headwinds, including a recent 8% revenue decrease and an anticipated $17-$18 billion revenue loss between 2026 and 2028 due to patent expirations. To counter these challenges, Pfizer is aggressively investing in its oncology pipeline, notably through the Seagen acquisition and a recent licensing agreement with 3SBio, aiming to launch eight new cancer medicines by 2030; however, the long-term sustainability of the dividend hinges on the successful execution of this growth strategy amid declining COVID-19 product revenues.

Analysis

Pfizer Inc. presents an attractive dividend yield, stated as 7.5% based on its annual $1.72 per share payout as of May 22, 2025, underpinned by a 16-year dividend increase track record and a seemingly healthy cash flow payout ratio of approximately 47.69%. However, this income appeal is tempered by significant underlying concerns, reflected in a cautious market sentiment (overall sentiment: -0.1, PFE sentiment: -0.2) and a high trailing twelve-month earnings-based payout ratio of 124.64%, indicating recent dividend payments exceeded reported profits. The company faces substantial revenue headwinds, exemplified by an 8% year-over-year decline in total revenues to $13.7 billion in Q1 2025, largely due to a 75% reduction in Paxlovid sales as COVID-19 demand normalized. More critically, Pfizer confronts an impending patent cliff, with key drugs like Eliquis, Prevnar, Ibrance, and Xtandi expected to cause an annual revenue loss of $17-$18 billion between 2026 and 2028. To counteract these pressures, Pfizer is aggressively pursuing a pipeline rejuvenation strategy centered on oncology, highlighted by the $43 billion acquisition of Seagen (which contributed $3.4 billion to fiscal year 2024 revenue) and a recent exclusive global licensing agreement with 3SBio for SSGJ-707, involving a $1.25 billion upfront payment and potentially up to $6 billion in total. The company aims to launch eight new cancer medicines by 2030, although drug development risks persist, as evidenced by the discontinuation of the oral GLP-1 candidate danuglipron in April 2025. The successful execution of this strategic shift is paramount for Pfizer to sustain its dividend and achieve long-term growth, navigating a challenging multi-year transition, with analysts currently holding a "Moderate Buy" rating and an average 12-month price target of $29.17.

Key Decisions for Investors

• Investors should critically assess the sustainability of Pfizer's approximately 7.5% dividend yield given the high earnings payout ratio of 124.64% and looming revenue declines from patent expirations, despite a more favorable cash flow coverage.
• Closely monitor milestones in Pfizer's oncology pipeline, including the integration of Seagen and progress towards its goal of launching eight new cancer drugs by 2030, as these are crucial for offsetting patent-driven revenue losses and supporting future dividend capacity.
• Consider the significant execution risk inherent in Pfizer's strategic pivot to oncology and the potential for dividend pressure if revenue replacement efforts fall short, warranting a cautious approach despite the current yield and analyst price targets.